Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study - Bhardwaj, Rajinder; Ivans, Andrea; Stringfellow, Joseph; Morris, Beth; Coric, Vladimir; Croop, Robert; Bertz, Richard (Clinical pharmacology in drug development, 2023)
Keywords: calcitonin gene–related peptide receptor antagonist; hepatic impairment; Pharmacokinetics; rimegepant; single dose; calcitonin gene-related peptide receptor antagonist; hepatic impairment; pharmacokinetics; single dose; rimegepant